CY1117842T1 - Πολυπεπτιδια μεταλλαγμενης il-2 - Google Patents
Πολυπεπτιδια μεταλλαγμενης il-2Info
- Publication number
- CY1117842T1 CY1117842T1 CY20161100718T CY161100718T CY1117842T1 CY 1117842 T1 CY1117842 T1 CY 1117842T1 CY 20161100718 T CY20161100718 T CY 20161100718T CY 161100718 T CY161100718 T CY 161100718T CY 1117842 T1 CY1117842 T1 CY 1117842T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptides
- mutant
- immunoconjugates
- mutual
- polynucleotide molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11153964 | 2011-02-10 | ||
EP11164237 | 2011-04-29 | ||
EP12702045.1A EP2673294B1 (de) | 2011-02-10 | 2012-02-07 | Mutante interleukin-2-polypeptide |
PCT/EP2012/051991 WO2012107417A1 (en) | 2011-02-10 | 2012-02-07 | Mutant interleukin-2 polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117842T1 true CY1117842T1 (el) | 2017-05-17 |
Family
ID=45560919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100718T CY1117842T1 (el) | 2011-02-10 | 2016-07-21 | Πολυπεπτιδια μεταλλαγμενης il-2 |
Country Status (36)
Country | Link |
---|---|
US (5) | US9266938B2 (de) |
EP (4) | EP3971206A1 (de) |
JP (2) | JP5878182B2 (de) |
KR (2) | KR101667096B1 (de) |
CN (3) | CN103492411B (de) |
AR (1) | AR085335A1 (de) |
AU (2) | AU2012215573B2 (de) |
BR (1) | BR112013018932B1 (de) |
CA (1) | CA2824253C (de) |
CL (1) | CL2013001987A1 (de) |
CO (1) | CO6741186A2 (de) |
CR (1) | CR20130314A (de) |
CY (1) | CY1117842T1 (de) |
DK (3) | DK3489255T3 (de) |
EA (1) | EA033369B1 (de) |
EC (1) | ECSP13012815A (de) |
ES (3) | ES2579987T3 (de) |
HK (1) | HK1217020A1 (de) |
HR (3) | HRP20160917T1 (de) |
HU (3) | HUE029139T2 (de) |
IL (3) | IL269687B (de) |
LT (2) | LT3075745T (de) |
MA (1) | MA35803B1 (de) |
MX (2) | MX340671B (de) |
MY (1) | MY190604A (de) |
PE (2) | PE20181077A1 (de) |
PH (1) | PH12017500954B1 (de) |
PL (3) | PL3075745T3 (de) |
PT (3) | PT2673294T (de) |
RS (3) | RS54802B1 (de) |
SG (2) | SG192673A1 (de) |
SI (3) | SI2673294T1 (de) |
TW (2) | TWI577801B (de) |
UA (2) | UA117294C2 (de) |
WO (1) | WO2012107417A1 (de) |
ZA (1) | ZA201305282B (de) |
Families Citing this family (232)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CN103052649B (zh) | 2010-07-29 | 2015-12-16 | Xencor公司 | 具有修改的等电点的抗体 |
MX358859B (es) | 2010-08-13 | 2018-09-05 | Roche Glycart Ag | Anticuerpos anti-fap y métodos de utilización. |
DK3489255T3 (da) | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Muterede interleukin-2-polypeptider |
EP2681244B1 (de) | 2011-03-02 | 2017-11-29 | Roche Glycart AG | Cea-antikörper |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CA3136084A1 (en) | 2011-06-01 | 2012-12-06 | Intrexon Actobiotics Nv | Polycistronic expression system for bacteria |
EP2747781B1 (de) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispezifische antikörper spezifisch für t-zell-aktivierende antigene und ein tumorantigen sowie verwendungsverfahren |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
ES2848732T3 (es) * | 2012-08-07 | 2021-08-11 | Roche Glycart Ag | Inmunoterapia mejorada |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
KR20150088881A (ko) * | 2012-11-30 | 2015-08-03 | 로슈 글리카트 아게 | 암세포 표적화된 mhc 클래스 i 포함 다중기능 단백질을 사용하는 순환 바이러스-특이적 세포독성 t-세포에 의한 암세포의 제거 |
SG11201504414UA (en) | 2012-12-21 | 2015-07-30 | Hoffmann La Roche | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
KR101833602B1 (ko) * | 2013-02-26 | 2018-02-28 | 로슈 글리카트 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
EP2961773B1 (de) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispezifische antigenbindende moleküle zur t-zellen-aktivierung |
US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
AU2014306271A1 (en) | 2013-08-08 | 2016-03-24 | The Scripps Research Institute | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
PL3102595T3 (pl) * | 2014-02-06 | 2019-04-30 | Hoffmann La Roche | Białka fuzyjne interleukiny-2 i ich zastosowania |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR20230022270A (ko) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
EP3129493B1 (de) | 2014-04-09 | 2021-07-07 | The Scripps Research Institute | Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern |
US10894828B2 (en) | 2014-07-10 | 2021-01-19 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
CA2954847A1 (en) * | 2014-07-21 | 2016-01-28 | Jeffrey Greve | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
NZ766556A (en) | 2014-08-04 | 2024-02-23 | Hoffmann La Roche | Bispecific t cell activating antigen binding molecules |
AU2015301936B2 (en) * | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
HUE047806T2 (hu) * | 2014-08-29 | 2020-05-28 | Hoffmann La Roche | Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel |
ES2871045T3 (es) | 2014-11-14 | 2021-10-28 | Hoffmann La Roche | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF |
EP4141032B1 (de) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Kombinationstherapie von t-zell-aktivierenden bispezifischen antigenbindenden molekülen und pd-1-achsen-bindenden antagonisten |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
WO2016100375A2 (en) | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
EP3973980A1 (de) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigenbindende moleküle mit einem trimeren liganden der tnf-familie |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
KR20180053674A (ko) | 2015-10-02 | 2018-05-23 | 에프. 호프만-라 로슈 아게 | 공자극 tnf 수용체에 특이적인 이중특이성 항체 |
AU2016329111A1 (en) | 2015-10-02 | 2018-02-08 | F. Hoffmann-La Roche Ag | Bispecific anti-CEAXCD3 T cell activating antigen binding molecules |
KR102146319B1 (ko) | 2015-10-02 | 2020-08-25 | 에프. 호프만-라 로슈 아게 | Pd1 및 tim3에 특이적인 이중특이성 항체 |
CA3003969A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
PE20181358A1 (es) | 2015-12-04 | 2018-08-22 | Novartis Ag | Composiciones de anticuerpo injertado con citoquina y metodos para su uso en inmunorregulacion |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
EP3178848A1 (de) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente |
CA2997406A1 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
WO2017106767A1 (en) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production of unnatural nucleotides using a crispr/cas9 system |
PL3400246T3 (pl) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3 |
AU2017208133B2 (en) | 2016-01-11 | 2023-12-21 | Universitat Zurich | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
RU2760997C2 (ru) | 2016-01-14 | 2021-12-02 | Интрексон Актобиотикс Н.В. | Композиции и способы для лечения диабета 1 типа |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
AU2017213659B2 (en) | 2016-02-05 | 2024-04-18 | Washington University | Compositions and methods for targeted cytokine delivery |
CN116813799A (zh) | 2016-02-05 | 2023-09-29 | 奥里尼斯生物科学私人有限公司 | Clec9a结合剂及其用途 |
CA3016849A1 (en) | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding single domain antibodies |
PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
CN109689087B (zh) | 2016-05-13 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | 靶向性突变干扰素-β及其用途 |
CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
MX2018015592A (es) | 2016-06-14 | 2019-04-24 | Xencor Inc | Anticuerpos inhibidores de puntos de control biespecificos. |
BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
DK3475295T3 (da) | 2016-06-24 | 2022-10-24 | Scripps Research Inst | Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR20190057113A (ko) | 2016-09-28 | 2019-05-27 | 조마 (유에스) 엘엘씨 | 인터루킨-2에 결합하는 항체 및 그 용도 |
WO2018060301A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies against cd3 |
AU2017342560B2 (en) | 2016-10-14 | 2022-03-17 | Xencor, Inc. | IL15/IL15Ralpha heterodimeric Fc-fusion proteins |
CN109952370B (zh) | 2016-10-19 | 2023-09-08 | 豪夫迈·罗氏有限公司 | 用于产生免疫缀合物的方法 |
EP3529264B1 (de) | 2016-10-24 | 2022-03-09 | Orionis Biosciences BV | Zielgerichtetes mutantes interferon-gamma und verwendungen davon |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
JP2019532996A (ja) * | 2016-11-08 | 2019-11-14 | デリニア,インコーポレーテッド | 自己免疫疾患を処置するためのil−2変異体 |
CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
US20190352363A1 (en) * | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
EP3577133A1 (de) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Gezielte chimäre proteine und verwendungen davon |
WO2018170168A1 (en) * | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
PE20191494A1 (es) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15 |
CN110382525B (zh) * | 2017-04-03 | 2023-10-20 | 豪夫迈·罗氏有限公司 | 免疫缀合物 |
TWI704158B (zh) * | 2017-04-04 | 2020-09-11 | 瑞士商赫孚孟拉羅股份公司 | 能夠特異性結合至cd40及fap之新穎雙特異性抗原結合分子 |
CN116375876A (zh) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
JP6928668B2 (ja) * | 2017-04-11 | 2021-09-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 増大した熱安定性を有する変異型逆転写酵素、ならびにそれに関する生成物、方法および使用 |
CN110505883A (zh) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
US20200362058A1 (en) * | 2017-05-24 | 2020-11-19 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
KR20200010354A (ko) | 2017-05-24 | 2020-01-30 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
CN110662762A (zh) * | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
EP3645122A1 (de) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Zielgerichtete heterodimere fc-fusionsproteine mit il-15/il-15ra und antigenbindenden domänen |
US20200131555A1 (en) | 2017-07-11 | 2020-04-30 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
EP3661955A4 (de) * | 2017-08-03 | 2021-05-26 | Synthorx, Inc. | Cytokin-konjugate zur behandlung von autoimmunerkrankungen |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3706793A1 (de) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispezifische und monospezifische antikörper unter verwendung von neuartigen anti-pd-1-sequenzen |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
EP3733716A4 (de) * | 2017-12-26 | 2021-11-24 | Nanjing GenScript Biotech Co., Ltd. | Fusionsproteindimer mit einer antikörper-fc-region als rückgrat und dessen verwendung |
CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
CA3115461A1 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
CN111918665A (zh) * | 2018-03-28 | 2020-11-10 | 阿森迪斯药物肿瘤股份有限公司 | Il-2缀合物 |
PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
BR112021000811A8 (pt) * | 2018-07-24 | 2022-10-18 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Agonistas de il2 |
CA3106324C (en) * | 2018-08-01 | 2024-04-02 | Nantkwest, Inc. | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for stable genetic modification of cellular immunotherapies |
AU2019337610A1 (en) * | 2018-09-11 | 2021-05-06 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
SG11202005873QA (en) * | 2018-09-17 | 2020-07-29 | Gi Innovation Inc | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
TW202023542A (zh) | 2018-09-18 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | 組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途 |
US20210213102A1 (en) * | 2018-09-21 | 2021-07-15 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
TWI791894B (zh) * | 2018-09-21 | 2023-02-11 | 大陸商信達生物製藥(蘇州)有限公司 | 新型白介素2及其用途 |
EP4321530A3 (de) * | 2018-09-27 | 2024-05-22 | Xilio Development, Inc. | Maskierte cytokinpolypeptide |
MX2021003765A (es) | 2018-10-03 | 2021-07-15 | Xencor Inc | Proteínas il-12 de fusión a fc heterodimérico. |
JP2022505871A (ja) * | 2018-10-23 | 2022-01-14 | ドラゴンフライ セラピューティクス, インコーポレイテッド | ヘテロ二量体fc融合タンパク質 |
BR112021008204A2 (pt) * | 2018-10-29 | 2021-08-10 | 1Globe Biomedical Co., Ltd. | novas composições de proteínas racionalmente projetadas |
US20220025007A1 (en) * | 2018-12-21 | 2022-01-27 | Hanmi Pharm. Co., Ltd. | Novel immunosuppressive interleukin 2 |
WO2020127369A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
WO2020127618A1 (en) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic cd28 antigen binding molecules |
BR112021010983A2 (pt) | 2018-12-21 | 2021-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | Variante de interleucina-2 humana ou seu derivado |
CN113924311A (zh) * | 2019-01-07 | 2022-01-11 | 印希比股份有限公司 | 包含修饰的il-2多肽的多肽及其用途 |
WO2020148612A1 (en) | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
EP3930850A1 (de) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Enpp3 und cd3 bindende heterodimere antikörper |
CN111647068A (zh) * | 2019-03-04 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素2变体或其衍生物 |
CN111944008A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种突变蛋白的方法以及得到的突变体蛋白 |
CN111944036A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
CA3136241A1 (en) | 2019-05-20 | 2020-11-26 | Ulrich Moebius | Il-2/il-15r.beta.y agonist dosing regimens for treating cancer or infectious diseases |
CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
JP2022536898A (ja) | 2019-06-12 | 2022-08-22 | アスクジーン・ファーマ・インコーポレイテッド | 新規il-15プロドラッグおよびその使用方法 |
WO2020252262A1 (en) | 2019-06-14 | 2020-12-17 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
KR20220035122A (ko) * | 2019-06-14 | 2022-03-21 | 큐진 인크. | 신규한 인터루킨-2 변이체 및 이의 이작용성 융합 분자 |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
EP3994169A1 (de) | 2019-07-02 | 2022-05-11 | F. Hoffmann-La Roche AG | Immunokonjugate mit einem mutierten interleukin-2 und einen anti-cd8-antikörper |
CA3148505A1 (en) * | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Novel il-2 fusion molecules |
US20220378933A1 (en) * | 2019-09-19 | 2022-12-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
WO2021059240A1 (en) | 2019-09-27 | 2021-04-01 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
IL292934A (en) | 2019-11-20 | 2022-07-01 | Gi Cell Inc | Composition of medium for t-cell culture and method for culture of t-cells using the same composition of medium |
CA3157592A1 (en) | 2019-11-20 | 2021-05-27 | Myoung Ho Jang | Composition for culturing natural killer cells and method for preparing natural killer cells by using same |
MX2022006000A (es) | 2019-11-20 | 2022-06-17 | Gi Cell Inc | Composicion de cultivo de linfocitos t reguladores y su uso. |
KR20210065874A (ko) | 2019-11-27 | 2021-06-04 | 주식회사 지아이셀 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 |
CA3161303A1 (en) * | 2019-11-27 | 2021-06-03 | Gi Innovation, Inc. | Pharmaceutical composition for treating cancer comprising fusion protein comprising il-2 protein and cd80 protein and immune checkpoint inhibitor |
CN111018961B (zh) * | 2019-12-17 | 2022-03-18 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
AU2020407208A1 (en) | 2019-12-17 | 2022-06-02 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
JP2023510115A (ja) | 2019-12-20 | 2023-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規il2アゴニストおよびそれらの使用方法 |
CA3167002A1 (en) * | 2020-01-09 | 2021-07-15 | Pfizer Inc. | Recombinant vaccinia virus |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
IL294388A (en) | 2020-01-14 | 2022-08-01 | Synthekine Inc | il2 orthologs and methods of use |
KR20240046306A (ko) | 2020-01-14 | 2024-04-08 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
TW202200608A (zh) | 2020-03-18 | 2022-01-01 | 南韓商Gi醫諾微新股份有限公司 | 包含il-2蛋白及cd80蛋白片段的融合蛋白或其變異體及其用途 |
EP4140495A4 (de) | 2020-03-18 | 2024-05-01 | Gi Innovation Inc | Pharmazeutische zusammensetzung zur krebsbehandlung mit fusionsprotein mit il-2-protein und cd80-protein und antikrebsmittel |
JP2023517511A (ja) | 2020-03-18 | 2023-04-26 | ジーアイ イノベーション, インコーポレイテッド | Il-2タンパク質とcd80タンパク質を含む融合タンパク質製剤 |
CA3175717A1 (en) * | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
WO2021185362A1 (zh) | 2020-03-19 | 2021-09-23 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
WO2021202675A1 (en) * | 2020-04-01 | 2021-10-07 | Xilio Development, Inc. | Masked il-2 cytokines and their cleavage products |
IL294451A (en) | 2020-04-15 | 2022-09-01 | Hoffmann La Roche | immune conjugates |
EP4139341A1 (de) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2-varianten mit reduzierter bindung an il-2-rezeptor-alpha und verwendungen davon |
CN115916811A (zh) | 2020-04-22 | 2023-04-04 | 默沙东有限责任公司 | 偏向于白介素-2受体βγc二聚体并缀合非肽水溶性聚合物的人白介素-2缀合物 |
CA3177288A1 (en) | 2020-05-11 | 2021-11-18 | F.Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
CN116323647A (zh) | 2020-05-13 | 2023-06-23 | 博纳姆治疗公司 | 蛋白质复合物的组合物及其使用方法 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
KR102373965B1 (ko) | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
IL296225A (en) | 2020-06-19 | 2022-11-01 | Hoffmann La Roche | Binding molecules in the fc domain that activate the immune system |
IL298402A (en) | 2020-06-19 | 2023-01-01 | Hoffmann La Roche | Antibodies that bind to CD3 and CD19 |
KR102313505B1 (ko) | 2020-06-30 | 2021-10-18 | (주)지아이이노베이션 | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
KR20220014531A (ko) * | 2020-07-29 | 2022-02-07 | (주)메디톡스 | 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법 |
TW202221031A (zh) | 2020-07-30 | 2022-06-01 | 英商阿法克塔生命科學有限公司 | 血清半衰期延長之pd-l1抑制多肽 |
US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
WO2022059794A1 (ja) * | 2020-09-18 | 2022-03-24 | 地方独立行政法人 宮城県立病院機構 | Il-2変異体タンパク質及びこれを含む医薬 |
CN114369153A (zh) * | 2020-10-18 | 2022-04-19 | 北京志道生物科技有限公司 | 一种白介素-2突变体 |
CN114380919A (zh) * | 2020-10-18 | 2022-04-22 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
IL302321A (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma |
AU2021372660A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
CA3195260A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
AU2021379816A1 (en) | 2020-11-13 | 2023-06-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof |
CN112724259B (zh) * | 2020-11-16 | 2022-12-20 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
CN116635403A (zh) | 2020-12-04 | 2023-08-22 | 豪夫迈·罗氏有限公司 | pH依赖性突变型白细胞介素-2多肽 |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
JP2024503703A (ja) * | 2021-01-19 | 2024-01-26 | セネカ セラピューティクス、インク. | 武装型セネカバレーウイルス腫瘍溶解療法組成物およびその方法 |
WO2022189377A1 (en) | 2021-03-09 | 2022-09-15 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
JP2024512382A (ja) | 2021-03-09 | 2024-03-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2バリアント免疫コンジュゲートと抗tyrp1/抗cd3二重特異性抗体の併用療法 |
EP4305065A1 (de) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Cd3 und gpc3 bindende heterodimere antikörper |
JP2024511465A (ja) | 2021-03-26 | 2024-03-13 | イナート・ファルマ・ソシエテ・アノニム | Nk細胞エンゲージングのためにサイトカインに融合したnkp46結合性部位、がん抗原結合性部位を含む多特異性タンパク質 |
EP4314032A1 (de) | 2021-03-30 | 2024-02-07 | F. Hoffmann-La Roche AG | Protease-aktivierte polypeptide |
KR20240005741A (ko) | 2021-04-09 | 2024-01-12 | 오제 이뮈노테라프틱스 | 특성이 향상된 이작용성 분자용 신규한 스캐폴드 |
CN116854802A (zh) * | 2021-04-13 | 2023-10-10 | 苏州复融生物技术有限公司 | 白介素2突变体及其应用 |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258673A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
AU2022288123A1 (en) | 2021-06-09 | 2023-11-30 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022266467A2 (en) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Recombinant histone polypeptide and uses thereof |
EP4366782A1 (de) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Konjugate von checkpoint-inhibitoren mit il-2 und verwendungen davon |
US20240158537A1 (en) | 2021-07-09 | 2024-05-16 | Bright Peak Therapeutics Ag | Synthetic il-7 and il-7 immunocytokines |
US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
KR20240040134A (ko) | 2021-07-09 | 2024-03-27 | 브라이트 피크 테라퓨틱스 아게 | 항체 접합체 및 이의 제조 |
AU2022325498A1 (en) | 2021-08-13 | 2024-02-01 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
WO2023025194A1 (zh) | 2021-08-24 | 2023-03-02 | 江苏恒瑞医药股份有限公司 | Fap/cd40结合分子及其医药用途 |
CN118019849A (zh) * | 2021-09-26 | 2024-05-10 | 上海药明生物技术有限公司 | Il-2变体及其融合蛋白 |
WO2023062050A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
CU20210104A7 (es) | 2021-12-21 | 2023-07-12 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 |
KR20230095612A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
US20230303650A1 (en) * | 2022-01-21 | 2023-09-28 | Aetio Biotherapy, Inc. | Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies |
EP4255924A4 (de) * | 2022-02-21 | 2024-02-14 | Ctcells Inc | Fusionsprotein mit einer antigenbindenden domäne und einem zytokintrimer |
US20240132563A1 (en) | 2022-02-23 | 2024-04-25 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
US20240076343A1 (en) | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024002363A1 (en) * | 2022-07-01 | 2024-01-04 | Beijing Neox Biotech Limited | Il-2 polypeptides and methods of use |
US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
WO2024037572A1 (en) * | 2022-08-16 | 2024-02-22 | Kine Biotech Co., Ltd. | Interleukin-2 variants and their uses in treating cancers |
WO2024068705A1 (en) | 2022-09-29 | 2024-04-04 | F. Hoffmann-La Roche Ag | Protease-activated polypeptides |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19607751A1 (de) | 1996-02-29 | 1997-09-04 | Henkel Kgaa | Neue Aminophenol-Derivate und deren Verwendung |
EP1106183A3 (de) | 1996-10-18 | 2001-09-12 | Genentech, Inc. | Antikörper gegen ErbB2 und deren therapeutische Verwendungen |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
EP1034298B1 (de) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanisierung von nager-antikörpern |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
EP2261229A3 (de) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glykosylierungs-Engineering von Antikörpern zur Verbesserung der antikörperabhängigen zellvermittelten Zytotoxizität |
EP0953639A1 (de) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-spezifischer Antikörper mit verbesserter Produzierbarkeit |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
AU776790B2 (en) | 1999-02-12 | 2004-09-23 | Lexigen Pharmaceuticals Corporation | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
NZ517906A (en) | 1999-10-04 | 2003-01-31 | Medicago Inc | Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants |
EP1268550A2 (de) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Humane und humanisierte fap-alpha-spezifische antikörper |
JP4936299B2 (ja) | 2000-08-21 | 2012-05-23 | メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ | 磁場方向検出センサ |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
PL367324A1 (en) | 2001-04-13 | 2005-02-21 | Biogen, Inc. | Antibodies to vla-1 |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US7371371B2 (en) | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
JP4795640B2 (ja) * | 2001-12-04 | 2011-10-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 調節された選択性を有する免疫サイトカイン |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
AU2003298187B2 (en) * | 2002-12-17 | 2010-09-16 | Merck Patent Gmbh | Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2 |
JP5425365B2 (ja) | 2003-01-22 | 2014-02-26 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 増加したFcレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用 |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
AU2004308452A1 (en) | 2003-12-22 | 2005-07-14 | Novartis Vaccines And Diagnostics, Inc. | Use of Fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
WO2005091956A2 (en) * | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
NZ550217A (en) | 2004-03-31 | 2009-11-27 | Genentech Inc | Humanized anti-TGF-beta antibodies |
ATE459648T1 (de) | 2005-05-11 | 2010-03-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
EP1806365A1 (de) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten |
CA2648484A1 (en) | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
WO2008003473A2 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
PL2066796T3 (pl) | 2006-09-20 | 2011-11-30 | Mt Biomethan Gmbh | Sposób i urządzenie do separacji metanu i dwutlenku węgla z biogazu |
WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
MX2009012343A (es) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
EP2183028A2 (de) | 2007-07-25 | 2010-05-12 | AstraZeneca AB | Gezielte bindungsmittel gegen kdr und ihre verwendungen |
EP2018877A1 (de) | 2007-07-27 | 2009-01-28 | The Procter and Gamble Company | Saugfähiger Artikel mit wasserabsorbierenden Polymerteilchen und Herstellungsverfahren dafür |
WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
EP3663318A1 (de) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Verfahren zur herstellung von fc-heterodimeren antikörpermolekülen unter verwendung von elektrostatischen steuereffekten |
ATE548052T1 (de) | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
CN102119175A (zh) | 2008-04-10 | 2011-07-06 | Ibc药品公司 | 采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法 |
ES2389474T3 (es) | 2008-05-13 | 2012-10-26 | Molmed Spa | Conjugados para el tratamiento del mesotelioma |
JP5766124B2 (ja) * | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
MX337590B (es) | 2009-01-29 | 2016-03-11 | Medimmune Llc | Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias. |
CA2756393C (en) * | 2009-03-24 | 2017-06-20 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
EP2448599A1 (de) | 2009-06-30 | 2012-05-09 | Philogen S.p.A. | Immunocytokine in kombination mit anti-erbb-antikörpern für krebsbehandlung |
MX2012002014A (es) | 2009-08-17 | 2012-06-13 | Roche Glycart Ag | Inmunoconjugados dirigidos. |
EP2473532B1 (de) | 2009-08-31 | 2017-06-21 | Roche Glycart AG | Affinitätsgereifte, humanisierte monoklonale anti-cea antikörper |
CA2773515C (en) | 2009-09-29 | 2015-04-28 | Roche Glycart Ag | Bispecific death receptor agonistic antibodies |
MX358859B (es) | 2010-08-13 | 2018-09-05 | Roche Glycart Ag | Anticuerpos anti-fap y métodos de utilización. |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
DK3489255T3 (da) | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Muterede interleukin-2-polypeptider |
EP2681244B1 (de) | 2011-03-02 | 2017-11-29 | Roche Glycart AG | Cea-antikörper |
HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
ES2848732T3 (es) | 2012-08-07 | 2021-08-11 | Roche Glycart Ag | Inmunoterapia mejorada |
PE20150645A1 (es) | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
CA2907597A1 (en) | 2013-05-07 | 2014-11-13 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules |
HUE047806T2 (hu) | 2014-08-29 | 2020-05-28 | Hoffmann La Roche | Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel |
-
2012
- 2012-02-07 DK DK18191941.6T patent/DK3489255T3/da active
- 2012-02-07 JP JP2013552930A patent/JP5878182B2/ja active Active
- 2012-02-07 PT PT127020451T patent/PT2673294T/pt unknown
- 2012-02-07 CA CA2824253A patent/CA2824253C/en active Active
- 2012-02-07 SG SG2013060207A patent/SG192673A1/en unknown
- 2012-02-07 ES ES12702045.1T patent/ES2579987T3/es active Active
- 2012-02-07 RS RS20160397A patent/RS54802B1/sr unknown
- 2012-02-07 ES ES16164244.2T patent/ES2694564T3/es active Active
- 2012-02-07 MY MYPI2013701387A patent/MY190604A/en unknown
- 2012-02-07 HU HUE12702045A patent/HUE029139T2/hu unknown
- 2012-02-07 EA EA201300896A patent/EA033369B1/ru not_active IP Right Cessation
- 2012-02-07 LT LTEP16164244.2T patent/LT3075745T/lt unknown
- 2012-02-07 SG SG10201604160WA patent/SG10201604160WA/en unknown
- 2012-02-07 UA UAA201611547A patent/UA117294C2/uk unknown
- 2012-02-07 SI SI201230620A patent/SI2673294T1/sl unknown
- 2012-02-07 TW TW101103928A patent/TWI577801B/zh active
- 2012-02-07 PL PL16164244T patent/PL3075745T3/pl unknown
- 2012-02-07 DK DK12702045.1T patent/DK2673294T3/en active
- 2012-02-07 PE PE2018000181A patent/PE20181077A1/es unknown
- 2012-02-07 HU HUE18191941A patent/HUE055284T2/hu unknown
- 2012-02-07 EP EP21178401.2A patent/EP3971206A1/de not_active Withdrawn
- 2012-02-07 DK DK16164244.2T patent/DK3075745T3/en active
- 2012-02-07 UA UAA201310726A patent/UA113729C2/uk unknown
- 2012-02-07 US US13/367,843 patent/US9266938B2/en active Active
- 2012-02-07 ES ES18191941T patent/ES2883371T3/es active Active
- 2012-02-07 WO PCT/EP2012/051991 patent/WO2012107417A1/en active Application Filing
- 2012-02-07 CN CN201280017730.1A patent/CN103492411B/zh active Active
- 2012-02-07 SI SI201231430T patent/SI3075745T1/sl unknown
- 2012-02-07 AU AU2012215573A patent/AU2012215573B2/en active Active
- 2012-02-07 KR KR1020137020938A patent/KR101667096B1/ko active IP Right Grant
- 2012-02-07 PL PL18191941T patent/PL3489255T3/pl unknown
- 2012-02-07 BR BR112013018932-0A patent/BR112013018932B1/pt active IP Right Grant
- 2012-02-07 RS RS20181250A patent/RS57767B1/sr unknown
- 2012-02-07 EP EP16164244.2A patent/EP3075745B1/de active Active
- 2012-02-07 TW TW106101987A patent/TWI666027B/zh not_active IP Right Cessation
- 2012-02-07 EP EP18191941.6A patent/EP3489255B1/de active Active
- 2012-02-07 LT LTEP18191941.6T patent/LT3489255T/lt unknown
- 2012-02-07 CN CN202010954354.5A patent/CN112210000A/zh active Pending
- 2012-02-07 PT PT16164244T patent/PT3075745T/pt unknown
- 2012-02-07 EP EP12702045.1A patent/EP2673294B1/de active Active
- 2012-02-07 MX MX2013009226A patent/MX340671B/es active IP Right Grant
- 2012-02-07 IL IL269687A patent/IL269687B/en unknown
- 2012-02-07 PE PE2013001855A patent/PE20140303A1/es active IP Right Grant
- 2012-02-07 KR KR1020157020539A patent/KR101852245B1/ko active IP Right Grant
- 2012-02-07 MX MX2016006214A patent/MX356675B/es unknown
- 2012-02-07 SI SI201231940T patent/SI3489255T1/sl unknown
- 2012-02-07 PT PT181919416T patent/PT3489255T/pt unknown
- 2012-02-07 CN CN201510970941.2A patent/CN105440123B/zh active Active
- 2012-02-07 PL PL12702045.1T patent/PL2673294T3/pl unknown
- 2012-02-07 HU HUE16164244A patent/HUE040326T2/hu unknown
- 2012-02-07 RS RS20210996A patent/RS62238B1/sr unknown
- 2012-02-08 AR ARP120100412A patent/AR085335A1/es active IP Right Grant
-
2013
- 2013-06-20 IL IL227095A patent/IL227095B/en active IP Right Grant
- 2013-06-24 CR CR20130314A patent/CR20130314A/es unknown
- 2013-06-25 CO CO13150839A patent/CO6741186A2/es unknown
- 2013-07-05 CL CL2013001987A patent/CL2013001987A1/es unknown
- 2013-07-12 ZA ZA2013/05282A patent/ZA201305282B/en unknown
- 2013-08-09 EC ECSP13012815 patent/ECSP13012815A/es unknown
- 2013-09-10 MA MA36237A patent/MA35803B1/fr unknown
-
2014
- 2014-03-27 HK HK16105003.6A patent/HK1217020A1/zh unknown
-
2015
- 2015-05-20 JP JP2015102866A patent/JP6155300B2/ja not_active Expired - Fee Related
- 2015-10-28 AU AU2015249085A patent/AU2015249085B2/en active Active
-
2016
- 2016-01-15 US US14/996,789 patent/US10323098B2/en active Active
- 2016-07-21 CY CY20161100718T patent/CY1117842T1/el unknown
- 2016-07-21 HR HRP20160917TT patent/HRP20160917T1/hr unknown
-
2017
- 2017-05-11 IL IL25223017A patent/IL252230B/en active IP Right Grant
- 2017-05-24 PH PH12017500954A patent/PH12017500954B1/en unknown
- 2017-12-20 US US15/849,501 patent/US10184009B2/en active Active
-
2018
- 2018-10-22 HR HRP20181736TT patent/HRP20181736T1/hr unknown
- 2018-11-21 US US16/198,531 patent/US11111312B2/en active Active
-
2019
- 2019-06-17 US US16/443,306 patent/US20190322765A1/en not_active Abandoned
-
2021
- 2021-08-16 HR HRP20211318TT patent/HRP20211318T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117842T1 (el) | Πολυπεπτιδια μεταλλαγμενης il-2 | |
CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
CY1122900T1 (el) | Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων | |
CY1120517T1 (el) | Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια | |
CY1122824T1 (el) | Πρωτεϊνες συντηξης και εμβολια συνδυασμου | |
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
CY1122490T1 (el) | Αντισωματα κατα του ανθρωπινου cd38 | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
CY1118702T1 (el) | Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου | |
MX2019014695A (es) | Proteinas de fusion de interleucina-2 y usos de las mismas. | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
EA201691078A1 (ru) | Терапевтические пептиды | |
PH12014502438A1 (en) | Prostate-associated antigens and vaccine-based immunotherapy regimens | |
PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
EA201490644A1 (ru) | Терапевтические пептиды | |
BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
MX2020003503A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
CY1124445T1 (el) | Αντισωματα αντι-ccl17 | |
CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
MX2016001691A (es) | Moleculas de union al receptor bag3 para uso como un medicamento. |